The Claim
In adults with type 2 diabetes initiating injectable therapy, GLP-1 receptor agonists are associated with a 44% lower hazard of severe hypoglycemia compared to basal insulin over a median follow-up of 24 months.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For adults with type 2 diabetes starting injectable treatment, GLP-1 receptor agonists are linked to a 44% lower risk of severe low blood sugar episodes compared to basal insulin over two years.
See the scientific wording
In adults with type 2 diabetes initiating injectable therapy, GLP-1 receptor agonists are associated with a 44% lower hazard of severe hypoglycemia compared to basal insulin over a median follow-up of 24 months, suggesting a safety advantage that may contribute to improved cardiovascular outcomes.
GLP-1 drugs make the pancreas release insulin only when blood sugar is high, and they stop the liver from releasing too much sugar, so blood sugar doesn't drop too low.
What the research says
1 studyPeople with type 2 diabetes who started a GLP-1 drug had fewer heart problems than those who started insulin, which suggests the GLP-1 drug is safer—likely because it causes fewer dangerous low blood sugar episodes.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.